GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Lin, Chien Yu ^a,b   Lin, Ting Yang ^b   Wang, Hung Ming ^a   Huang, Shiang Fu ^a   Fan, Kang Hsing ^a,b   Liao, Chun Ta ^a   Chen, I How ^a   Lee, Li Yu ^a,b   Li, Yen Liang ^b   Chen, Yin Ju ^b   Cheng, Ann Joy ^b   Chang, Joseph T ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Gp96; Oral cavity cancers; Prognosis; Radioresistance

Indexed keywords

CISPLATIN; FOLINIC ACID; GLYCOPROTEIN GP 96; ENDOPLASMIN; FLUORODEOXYGLUCOSE F 18; MEMBRANE PROTEIN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MOUTH MUCOSA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING; BIOSYNTHESIS; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; MOUTH TUMOR; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY;

EID: 80053903699     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-136     Document Type: Article

References (18)

1. Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF, Cheng AJ. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci 2008, 99:1507-1514. 10.1111/j.1349-7006.2008.00863.x, 18754860.
2. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 1995, 24:450-453. 10.1111/j.1600-0714.1995.tb01132.x, 8600280.
3. Clinical practice guidelines in cancer of oral cavity. National Comprehensive Cancer Network 2008, version 2., http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
4. Gonzalez-Garcia R, Naval-Gias L, Roman-Romero L, Sastre-Perez J, Rodriguez-Campo FJ. Local recurrences and second primary tumors from squamous cell carcinoma of the oral cavity: a retrospective analytic study of 500 patients. Head Neck 2009, 31:1168-1180. 10.1002/hed.21088, 19408289.
5. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol 2008, 15:915-922. 10.1245/s10434-007-9761-5, 18165878.
6. Lin CY, Lee LY, Huang SF, Kang CJ, Fan KH, Wang HM, Chen EY, Chen IH, Liao CT, Cheng AJ, et al. Treatment outcome of combined modalities for buccal cancers: unilateral or bilateral neck radiation?. Int J Radiat Oncol Biol Phys 2008, 70:1373-1381. 10.1016/j.ijrobp.2007.08.022, 18374224.
7. Fan KH, Lin CY, Kang CJ, Huang SF, Wang HM, Chen EY, Chen IH, Liao CT, Cheng AJ, Chang JT. Combined-modality treatment for advanced oral tongue squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007, 67:453-461. 10.1016/j.ijrobp.2006.06.026, 17236967.
8. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett 2007, 581:3641-3651. 10.1016/j.febslet.2007.04.045, 2040386, 17481612.
9. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006, 31:164-172. 10.1016/j.tibs.2006.01.006, 16483782.
10. Nicchitta CV. Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96. Curr Opin Immunol 1998, 10:103-109. 10.1016/S0952-7915(98)80039-3, 9523119.
11. Fu Y, Lee AS. Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther 2006, 5:741-744. 10.4161/cbt.5.7.2970, 16861902.
12. Wang XP, Liu GZ, Song AL, Chen RF, Li HY, Liu Y. Expression and significance of heat shock protein 70 and glucose-regulated protein 94 in human esophageal carcinoma. World J Gastroenterol 2005, 11:429-432.
13. Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF, Takano Y. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol 2008, 39:1042-1049. 10.1016/j.humpath.2007.11.009, 18482745.
14. Chang JT, Chan SH, Lin CY, Lin TY, Wang HM, Liao CT, Wang TH, Lee LY, Cheng AJ. Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol Cancer Ther 2007, 6:2271-2279. 10.1158/1535-7163.MCT-06-0801, 17671084.
15. Lin TY, Chang JT, Wang HM, Chan SH, Chiu CC, Lin CY, Fan KH, Liao CT, Chen IH, Liu TZ, et al. Proteomics of the radioresistant phenotype in head-and-neck cancer: Gp96 as a novel prediction marker and sensitizing target for radiotherapy. Int J Radiat Oncol Biol Phys 2010, 78:246-256. 10.1016/j.ijrobp.2010.03.002, 20615631.
16. Bernier J, Cooper JS, Pajak TF, van GM, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005, 27:843-850. 10.1002/hed.20279, 16161069.
17. Wang XP, Qiu FR, Liu GZ, Chen RF. Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma. World J Gastroenterol 2005, 11:1056-1059.
18. Kubota H, Suzuki T, Lu J, Takahashi S, Sugita K, Sekiya S, Suzuki N. Increased expression of GRP94 protein is associated with decreased sensitivity to X-rays in cervical cancer cell lines. Int J Radiat Biol 2005, 81:701-709. 10.1080/09553000500434727, 16368648.